Monograph: |
Haemocoagulase
Batroxobin(haemocoagulase)is an enzyme obtained from the venom
of the viper Bothrops atrox. It has also been obtained from
Bothrops moojeni and a similar preparation is derived from
Bothrops jararaca. The name haemocoagulase (hemocoagulase) is
used for a preparation of batroxobin with a factor-X activator.
Batroxobin is reported to act on fibrinogen to produce a fibrin
monomer that can be converted by thrombin to a fibrin clot. It
is used both as a haemostatic and, in larger doses, to
induce a hypofibrinogen state in the management of thrombo-
embolic disorders . When used as a haemostatic it is
usually given with a factor-X activator as haemocoagulase.
Administration of batroxobin may be by parenteral routes or
by local application.
BotroClot (R)
TOPICAL SOLUTION
(Sterile Haemocoagulase solution)
BotroClot Topical Solutton is a haemocoagulant. The principal active
Ingredient is the purified Haemocoagulase enzyme complex isolated from
Bothrops atrox or Bothrops jararaca. BotroClot. Topical Solution is atoxic
Botroclot Topical Solution is instantaneously effective in arresting capillary
Bleeding by accelerating the physiological process of hemostasis.
COMPOSITION
Each ml of BotroClot* Topical Solution contains:
Aqueous solution of Haemocoagulase Isolated from Bothrops atrox or
Bothrops jararaca 0.2 CU, Chlorhexidine Gluconate Solution IP** 1% v/v,
Water for injection IP q.s.
("as preservative)
MECHANISM OF ACTION
BotroClot* (Haemocoagulase) has muttifaceted haemocoagulant action. The
thrombin like action of BotroClot* rapidly converts fibrinogen to fibrin
monomer by releasing fibrinopeptide. A from the fibrinogen. These fibrin
monomers polymerise end-to-end to form a cross-linked fibrin clol
Fibrinopeptide-A free fibrin monomer, in the circulating blood, forms a complex
with the native fibrinogen, which promotes the platetet aggregation and
reduces the capillary permeability at the vascular damage site. The
thromboplastin like enzymatic activity of BotroClot* at the site of bleeding
activates the factor X. The activated factor Xa, then helps in the formation of
thrombin at the site of haemorrhage. Hence, BotroClot* can be used in
patients with normal haemocoagulant factors or in patients showing anomalies
in the coagulation biochemical process. Thrombin inhibitors like heparin does
not affect the thrombin like activity of BotroClot* Thus. BotroClot* shortens
both the bleeding and coagulation time and saves every drop of blood. On
topical application the blood coagulation process starts immediately.
INDICATIONS:
BotroClot* Topical Solution is indicated in localised capillary haemorrhages
DIRECTIONS FOR USE:
Apply 5 to 10 drops or more onto site of bleeding, depending on the intensity
Of bleeding.
Not for injection.
CAUTION;
Do not touch the dropper to any surface since this may contaminate
OVERDOSAGE / TOXICITY
BotroClot* is virtually free from toxicity. BotroClot* is atoxic, reaction free and safe
Use in Pregnancy and Lactation
Teratogenic effects have not so far been demonstrated. However, BotroClot* should not be used during the first 3 months of pregnancy, except in emergencies. As no reports on effects of BortoClot* during lactation are available. It should not be used for lactating mothers except in emergencies.
CONTRAINDICATION
Thrombophilic condition : In view of its strong coagulation action,
BotroClot* is contraindicated in cases of venous of arterial thrombosis and as a general rule in diseases with tendency to intravascular.
|